X0303 4 2010-10-27 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001402393 Advent Partners HLS III Limited Partnership C/O ADVENT INTERNATIONAL CORPORATION 75 STATE STREET, 29TH FLOOR BOSTON MA 02109 0 0 0 1 Member of Group > 10% Common Stock 49 D Common Stock 2010-10-27 4 C 0 13962 A 14011 D Common Stock 2010-10-27 4 C 0 4878 A 18889 D Common Stock 2010-10-27 4 C 0 8952 7.60 A 27841 D Common Stock 2010-10-27 4 P 0 2895 9.50 A 30736 D Series A Convertible Preferred Stock 0.00 2010-10-27 4 C 0 36079 0.00 D Common Stock 13962 0 D Series B Convertible Preferred Stock 0.00 2010-10-27 4 C 0 7994 0.00 D Common Stock 4878 0 D Senior Subordinated Convertible Promissory Notes 7.60 2010-10-27 4 C 0 68057.88 0.00 D 2011-12-31 Common Stock 8952 0.00 D Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares") and each share of the Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, immediately converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. The Series A Shares converted on a 1-for-0.38701117412 basis and the Series B Shares converted on a 1-for-0.61027657931 basis. The Series A Shares and the Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date. Shares acquired upon the closing of the Issuer's initial public offering at the initial public offering price of $9.50 per share. The outstanding principal and accrued and unpaid interest on these senior subordinated convertible promissory notes (the "Convertible Notes") automatically converted into shares of common stock upon the closing of the Issuer's initial public offering, at $7.60 per share, 80% of the Issuer's initial public offering price per share. /s/ Jarlyth H. Gibson, Compliance Officer 2010-10-27